Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Opdivo Qvantig Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0281

    Opdivo Qvantig (nivolumab hyaluronidase-nvhy) Coverage Criteria

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0281 alerts

    Get alerted when Policy CC-0281 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit clinical review and prior authorization for Opdivo Qvantig, including FDA-labeled and NCCN-supported oncology uses for specified cancers.

    Policy Summary
    PayerEmpire Bluecross
    PolicyOpdivo Qvantig (nivolumab hyaluronidase-nvhy) Coverage Criteria
    Policy CodePolicy CC-0281
    Change TypeModified
    Effective DateSeptember 18, 2026
    Last ReviewJun 8, 2026
    Next Review DateN/A
    Key ActionSubmit prior-authorization documentation showing the qualifying cancer diagnosis, intended regimen and treatment line, required biomarkers, prior therapies, and performance status.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added step therapy requiring inability to use intravenous Opdivo because of no venous access as a qualifying circumstance for Opdivo Qvantig.

    The June 8, 2026 review revised multiple oncology indication criteria, including ampullary adenocarcinoma, anal carcinoma, appendiceal adenocarcinoma, bone cancer, CLL/SLL, colorectal cancer, uterine neoplasms, hepatocellular carcinoma, melanoma, Merkel cell carcinoma, and NSCLC.

    The policy removed criteria for Hodgkin lymphoma, pediatric classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, extranodal NK/T-cell lymphomas, and pediatric CNS diffuse high-grade gliomas because they were not included in NCCN or FDA guidance for Opdivo Qvantig.

    The coding list was revised by adding ICD-10-CM codes C24.1, C96.20, C96.29, C96.A, and C96.9 and removing multiple diagnosis-code ranges.

    Effective October 1, 2026, Opdivo is the preferred agent and Opdivo Qvantig is the non-preferred agent under the Commercial Medical Benefit.

    Medicaid Medical Benefit agent preference transitions by jurisdiction between September 1 and December 1, 2026, with Opdivo preferred and Opdivo Qvantig non-preferred.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10FDA-indicated cancer categories
    No venous accessStep-therapy exception
    Not approvedUnapproved combination or indication
    10/01/2026Commercial benefit preference effective
    09/01–12/01/2026Medicaid preference transition

    Covered Indications and Limitations

    Clinical Criteria Pathways—Part 1

    Covered when the individual meets at least one of the following pathways. Where a pathway contains an AND branch, all listed conditions apply.

    ONE of the following clinical pathways

    • ANY of the following

      • I

        • Individual is under 19 years of age.
      • II

        • Diagnosis of ampullary adenocarcinoma.
        • Disease is deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H).
        • Use

          • First-line therapy for intestinal metastatic disease.
          • Treatment of disease progression when there has been no prior immunotherapy.
      • III

        • Diagnosis of anal carcinoma (NCCN 2A).
        • Use as a single agent or in combination with paclitaxel and carboplatin.
      • IV

        • Diagnosis of appendiceal adenocarcinoma (NCCN 2A).
        • Use as a single agent with no prior checkpoint-inhibitor treatment.
        • Disease has dMMR/MSI-H or a POLE/POLD1 mutation with an ultra-hypermutated phenotype (for example, TMB >50 mut/Mb).
      • V

        • Treatment of bone cancer (NCCN 2A).
        • Use as monotherapy or with sunitinib for dedifferentiated chondrosarcoma (NCT03277924).
        • No prior anti-PD-1 or anti-PD-L1 agent.
        • Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
      • VI

        • Diagnosis of cervical cancer (NCCN 2A).
        • Use as a single agent for second-line or subsequent therapy.
        • CPS ≥1 for local/regional recurrence, stage IVB disease, or recurrence with distant metastases.
      • VII

        • Diagnosis of chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) (NCCN 2A).
        • Use as a single agent or with ibrutinib.
        • Histologic (Richter) transformation to diffuse large B-cell lymphoma.

    Colorectal and Uterine Cancers

    Coverage for colorectal and uterine neoplasms requires the applicable diagnosis, treatment setting, biomarker status, and prior-therapy conditions below.

    ONE of the following

    • VIII—Resectable colorectal cancer

      • Diagnosis of colorectal cancer (NCCN 2A).
      • Use as monotherapy for resectable disease as neoadjuvant or initial treatment, including clinical T4b disease or bulky nodal disease.
      • Tumor is dMMR/MSI-H or has a POLE/POLD1 mutation with an ultra-hypermutated phenotype (for example, TMB >50 mut/Mb).
      • No prior anti-PD-1 or anti-PD-L1 agent.
      • Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.

    Esophageal, Gastric, and Esophagogastric-Junction Cancers

    Coverage is available for the following esophageal, gastric, and esophagogastric-junction cancer pathways.

    ONE of the following

    • XI—Advanced ESCC, first line

      • Unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) (label, NCCN 1 or 2A).
      • Use with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment.
      • Current ECOG performance status 0–2.
      • No prior checkpoint-inhibitor therapy, or no tumor progression while receiving a checkpoint inhibitor.
      • Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.

    Hepatocellular, Histiocytic, Sarcoma-Related, Melanoma, and Merkel Cell Indications

    Coverage includes the following hepatocellular, histiocytic, sarcoma-related, gestational trophoblastic, mesothelioma, and melanoma pathways.

    ONE of the following

    • XIX—Hepatocellular carcinoma

      • Advanced hepatocellular carcinoma (label, NCCN 2A).
      • Use as a single agent for subsequent therapy with no prior checkpoint-inhibitor treatment.
    • XX—Histiocytic neoplasms

      • Primary malignant histiocytic neoplasm (NCCN 2A).
      • Use as a single agent for first-line or subsequent therapy.

    Head and Neck, Urothelial, Thyroid, Gynecologic, and Skin Cancers

    Coverage includes the following head and neck, urothelial, thyroid, and selected gynecologic and skin-cancer pathways.

    ONE of the following

    • XXXIV—Recurrent or metastatic SCCHN

      • Recurrent, unresectable, or metastatic squamous cell carcinoma of the head and neck (label, NCCN 1).
      • Regimen

        • Monotherapy after progression on or after platinum-containing chemotherapy.
        • Combination with cetuximab for first-line or subsequent therapy (NCCN 2A).
    • XXXV—Nasopharyngeal cancer

    Selected Disease-Specific Criteria

    Additional covered disease-specific pathways are listed below.

    ONE of the following

    • XL—Vaginal cancer

      • Recurrent or metastatic vaginal cancer (NCCN 2A).
      • Use as a single agent for second-line or subsequent therapy.
      • PD-L1-positive tumor (CPS ≥1%) or HPV-related tumor.
    • XLI—Vulvar cancer

      • Advanced or recurrent metastatic vulvar cancer (NCCN 2A).

    Opdivo Qvantig may be substituted for intravenous nivolumab where the applicable FDA label or NCCN recommendation supports nivolumab. The package insert states that Opdivo Qvantig is not indicated in combination with ipilimumab (Yervoy).

    Opdivo Qvantig is not approved for use in combination with intravenous ipilimumab.

    Indications that do not meet one of the listed clinical criteria, and all other indications, are not approved under this policy.

    Combination treatment with intravenous ipilimumab is not an approved use of Opdivo Qvantig.

    Approval requires that the individual satisfy the applicable diagnosis, treatment, biomarker, prior-therapy, performance-status, and exclusion criteria in a covered pathway. Uses outside those criteria are not approved.

    Uses outside the specified covered cancer diagnoses and treatment pathways are not medically necessary or approved under this policy.

    Initial Authorization Requirements

    Disease-Specific Initial Therapy

    Initial or disease-specific treatment is available through the applicable diagnosis-specific pathway and is subject to the listed biomarker, treatment-line, prior-therapy, and combination requirements.

    Applicable initial or disease-specific pathway

    • Diagnosis and regimen: Individual has a covered cancer diagnosis and the requested Opdivo Qvantig regimen is specified as monotherapy or combination therapy in the applicable disease-specific criteria.
    • Treatment setting: The requested treatment setting is the applicable first-line, second-line or subsequent, neoadjuvant, adjuvant, postoperative, or palliative setting identified for the diagnosis.
    • Biomarker and prior-treatment conditions: The individual meets all applicable biomarker, prior-treatment, disease-progression, performance-status, and safety conditions for the selected pathway.

    Coding and Clinical Thresholds

    Diagnosis CodeICD-10
    D09.0Carcinoma in situ of bladder
    HCPCSHCPCS
    J9289Injection, nivolumab, 2 mg and hyaluronidase-nvhy [Opdivo Qvantig]
    ICD-10 DiagnosisICD-10
    C00.0-C06.9Malignant neoplasm of lip, tongue, oral cavity
    C09.0-C13.9Malignant neoplasm of tonsil, oropharynx, nasopharynx, pyriform sinus, hypopharynx
    C14.0-C14.8Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx
    C15.0-C16.9Malignant neoplasm of esophagus, stomach
    C17.0-C20Malignant neoplasm of small intestine, colon, rectosigmoid junction, rectum
    C21.0-C21.8Malignant neoplasm of anus and anal canal
    C22.0Liver cell carcinoma
    C22.8Malignant neoplasm of liver, primary, unspecified as to type
    C22.9Malignant neoplasm of liver, not specified as primary or secondary
    C24.1Malignant neoplasm of ampulla of Vater
    1–10 of 53
    1/6
    Resectable NSCLC
    Tumor-size thresholdResectable NSCLC tumors are defined as ≥ 4 cm.
    Additional resectability criterionNode-positive disease also meets the stated resectable NSCLC definition.
    Neoadjuvant regimenTreatment is given with platinum-doublet chemotherapy, followed by adjuvant Opdivo Qvantig monotherapy after surgery when applicable.
    Cervical cancer
    CPS thresholdCPS must be ≥ 1.
    Treatment settingThe cervical cancer pathway applies to single-agent, second-line or subsequent therapy.

    Authorization, Documentation, and Denial Risks

    Note

    Clinical Review May Be Required

    When Opdivo Qvantig is reviewed under the member’s medical benefit or is otherwise subject to clinical review, including prior authorization, the request is evaluated against applicable medical-necessity criteria for the intended use.

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required when applicable. The request must document a covered indication and satisfy all applicable clinical criteria before Opdivo Qvantig may be approved.

    • Approval is limited to the listed FDA-labeled or NCCN-supported indications and regimens.
    • Requests that do not meet the applicable criteria may be denied.
    Prior Authorization

    Sequencing and Preferred-Agent Requirements

    StepRequirementExamples of applicable sequencing
    1Meet the applicable disease-specific sequencing requirement before using Opdivo Qvantig.Depending on the diagnosis, this may include prior intravenous nivolumab plus ipilimumab; prior anti-angiogenic therapy; platinum-based chemotherapy; fluoropyrimidine, oxaliplatin, and irinotecan; sorafenib; or specified neoadjuvant/adjuvant therapy.
    StepExceptionRequired documentation
    1The individual is unable to use intravenous Opdivo (nivolumab) because of no venous access.Document the inability to use intravenous Opdivo because the individual has no venous access.
    BenefitPreferred agentNon-preferred agentEffective date
    Commercial Medical BenefitOpdivoOpdivo QvantigOctober 1, 2026
    JurisdictionEffective datePreferred agentNon-preferred agent
    MD, NY, WNYSeptember 1, 2026OpdivoOpdivo Qvantig
    WA, NJ, OH, VAOctober 1, 2026OpdivoOpdivo Qvantig
    CA, IANovember 1, 2026OpdivoOpdivo Qvantig
    ARDecember 1, 2026OpdivoOpdivo Qvantig

    Drug and Policy Background

    Opdivo Qvantig (nivolumab hyaluronidase-nvhy) combines the PD-1-blocking antibody nivolumab with hyaluronidase and may be substituted for intravenous nivolumab when the applicable policy criteria are met. The policy permits substitution where Opdivo has an NCCN 1 or 2A recommendation for monotherapy or combination chemotherapy. Opdivo Qvantig is not indicated in combination with ipilimumab (Yervoy).

    Clinical Terms and Biomarker Definitions

    Adjuvant therapy
    DefinitionTreatment given after the primary treatment to increase the chances of a cure.
    ExamplesAdjuvant therapy may include chemotherapy, radiation, hormone therapy, or biological therapy.
    Policy contextAdjuvant Opdivo Qvantig is specified after surgery in certain resectable NSCLC pathways.
    ECOG performance status
    PurposeA scale used to assess how disease affects daily living, treatment suitability, and prognosis.
    Score 0Fully active and able to carry on all pre-disease performance without restriction.
    Score 1–2
    Policy Summary
    PayerEmpire Bluecross
    PolicyOpdivo Qvantig (nivolumab hyaluronidase-nvhy) Coverage Criteria
    Policy CodePolicy CC-0281
    Change TypeModified
    Effective DateSeptember 18, 2026
    Last ReviewJun 8, 2026
    Next Review DateN/A
    Key ActionSubmit prior-authorization documentation showing the qualifying cancer diagnosis, intended regimen and treatment line, required biomarkers, prior therapies, and performance status.
    SourceLink
    On This Page
    Covered Indications and LimitationsInitial Authorization RequirementsCoding and Clinical ThresholdsAuthorization, Documentation, and Denial RisksSequencing and Preferred-Agent RequirementsDrug and Policy BackgroundClinical Terms and Biomarker Definitions
  1. IX—Metastatic colorectal cancer

    • Diagnosis of colorectal cancer (label, NCCN 2A).
    • Metastatic disease with dMMR/MSI-H that progressed after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
    • Use as monotherapy.
    • No prior immunotherapy.
  2. X—Uterine neoplasms

    • Diagnosis of uterine neoplasm, including endometrial carcinoma or uterine sarcoma (NCCN 2A).
    • Recurrent MSI-H or dMMR disease.
    • Use as a single agent for second-line or subsequent therapy.
    • No prior anti-PD-1 or anti-PD-L1 agent.
    • Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
  3. XII—Advanced ESCC, subsequent therapy

    • Unresectable locally advanced, recurrent, or metastatic ESCC (label, NCCN 2A).
    • Use as a single agent for second-line or subsequent therapy.
  4. XIII—Completely resected esophageal/EGJ cancer

    • Completely resected esophageal or esophagogastric-junction cancer with residual pathologic disease (label, NCCN 1).
    • Use as a single agent after neoadjuvant chemoradiotherapy.
    • Current ECOG performance status 0–2.
    • No prior anti-PD-1, anti-PD-L1, or other checkpoint-inhibitor treatment.
    • Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
  5. XIV—MSI-H/dMMR postoperative disease

    • Gastric, esophageal, or esophagogastric-junction cancer with MSI-H or dMMR tumor (NCCN 2A).
    • Adenocarcinoma treated as a single agent for postoperative management after complete resection in an individual who received preoperative intravenous nivolumab plus ipilimumab.
    • Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
  6. XV—Advanced or metastatic gastric/EGJ cancer

    • Advanced or metastatic gastric, esophageal, or esophagogastric-junction cancer.
    • Use with fluoropyrimidine or capecitabine and platinum-containing chemotherapy.
    • HER2-negative disease.
    • Current ECOG performance status 0–2.
    • No prior checkpoint-inhibitor therapy, or no tumor progression while receiving a checkpoint inhibitor.
    • Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
  7. XVI/XVII—Gastric or EGJ palliative therapy

    • Gastric or esophageal/esophagogastric-junction cancer requiring palliative care (NCCN 1 or 2A).
    • Not a surgical candidate or has unresectable locally advanced, recurrent, or metastatic disease.
    • Disease and regimen

      • ALL of the following

        • MSI-H/dMMR tumor.
        • First-line treatment with fluoropyrimidine and oxaliplatin.
      • ALL of the following

        • Squamous cell carcinoma.
        • First-line treatment with fluoropyrimidine- and platinum-containing chemotherapy, or second-line or subsequent monotherapy.
    • Disease progression on, or intolerance to, fluoropyrimidine- and platinum-based chemotherapy.
    • Current ECOG performance status 0–2 or Karnofsky performance score 60–100.
    • Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
  8. XXI—Classic Kaposi sarcoma

    • Relapsed/refractory advanced classic Kaposi sarcoma (NCCN 2A).
    • Use as a single agent for subsequent systemic therapy.
    • No multicentric Castleman disease or KSHV-associated inflammatory cytokine syndrome.
  9. XXII—Mesothelioma

    • Malignant pleural or peritoneal mesothelioma (NCCN 2A).
    • Use as a single agent for subsequent therapy.
    • Current ECOG performance status 0–2.
    • Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
  10. XVIII—Gestational trophoblastic neoplasia

    • Multi-agent chemotherapy-resistant gestational trophoblastic neoplasia (NCCN 2A).
    • Recurrent or progressive intermediate trophoblastic tumor or high-risk disease.
    • Use as single-agent therapy.
    • No prior anti-PD-1 or anti-PD-L1 agent.
    • Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
  11. XXIII/XXIV—Cutaneous melanoma

    • Diagnosis of cutaneous melanoma (NCCN 1 or 2A).
    • Treatment setting

      • Systemic neoadjuvant therapy, with or without ipilimumab, and no prior immunotherapy when combination therapy is used.
      • Systemic adjuvant monotherapy for stage IIB/IIC disease, resectable limited disease, local satellite/in-transit recurrence, resectable nodal recurrence, or oligometastatic disease.
      • Metastatic or unresectable disease treated as first-line or subsequent monotherapy.
  12. XXV—Melanoma with brain metastases

    • Primary melanoma with metastatic brain disease.
    • Asymptomatic brain metastases, including BRAF-nonspecific asymptomatic brain metastases.
    • Use as monotherapy.
  13. XXVI—Uveal melanoma

    • Metastatic or unresectable uveal melanoma (NCCN 2A).
    • Use as a single agent.
  14. XXVII—Merkel cell carcinoma

    • Merkel cell carcinoma (NCCN 2A).
    • Covered setting

      • Single-agent neoadjuvant therapy for primary clinical N0 locally advanced disease when curative surgery and curative radiation were originally deemed infeasible.
      • Single-agent neoadjuvant therapy for primary N+, M0 regional disease.
      • Single-agent therapy for primary N+, M0 regional disease, recurrent N+ regional disease, in-transit N+ regional disease, or M1 disseminated disease when curative surgery and radiation are not feasible as applicable.
  15. Recurrent, unresectable, oligometastatic, or metastatic nasopharyngeal cancer (NCCN 2A).
  16. No surgery or radiotherapy options.
  17. Use with cisplatin and gemcitabine.
  18. No prior anti-PD-1 or anti-PD-L1 agent.
  19. XXXVI—Anaplastic thyroid carcinoma

    • Metastatic anaplastic thyroid carcinoma (NCCN 2A).
    • Use as a single agent.
  20. XXXVII/XXXVIII/XXXIX—Urothelial carcinoma

    • ALL of the following

      • Locally advanced, recurrent, or metastatic urothelial carcinoma.
      • Use as a single agent after progression on or after platinum-containing or other chemotherapy, or progression within 12 months of neoadjuvant/adjuvant platinum-containing chemotherapy.
    • ALL of the following

      • Unresectable, recurrent, or metastatic urothelial carcinoma.
      • Use with cisplatin and gemcitabine as first-line treatment.
    • ALL of the following

      • Urothelial carcinoma of the prostate with stromal invasion, when platinum-based neoadjuvant chemotherapy was not given and disease is pT3, pT4a, or pN+.
      • Use as a single agent.
  21. Use as a single agent, including adjuvant therapy when the individual is at high risk of recurrence after radical resection.
  22. Squamous cell skin cancer

    • Diagnosis of squamous cell skin cancer (NCCN 2A).
    • Use under the applicable listed disease-specific pathway.
  23. Molecular-marker assessment

    • Before initiating therapy, assess actionable markers including EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, ERBB2 (HER2), and NRG1 mutations.
    • If tissue is insufficient for testing, repeat biopsy and/or plasma testing should be performed when feasible.
    • If testing is not feasible, treatment is guided by available results; when unknown, treat as though driver oncogenes are absent.
  24. Covered Initial Therapy

    Initial authorization is available only for a listed diagnosis and regimen with all applicable disease, biomarker, treatment-line, prior-treatment, performance-status, and safety conditions documented.

    Initial authorization requirements

    • Covered indication: The request identifies a cancer diagnosis and disease extent or stage included in the covered clinical criteria.
    • Regimen and treatment line: The request specifies whether Opdivo Qvantig will be used as monotherapy or in combination therapy and identifies the applicable treatment line or treatment setting.
    • Pathology and biomarkers: Required pathology and biomarker results are documented, including applicable MSI-H/dMMR, POLE/POLD1, TMB, HER2, PD-L1, HPV, BRAF, EGFR, or ALK results.
    • Prior treatment and response: Applicable prior chemotherapy, neoadjuvant treatment, immunotherapy, anti-angiogenic therapy, progression, intolerance, or absence of prior checkpoint-inhibitor therapy is documented.
    • Performance status and safety: Applicable ECOG or Karnofsky performance status, surgical or radiation feasibility, contraindication status, and autoimmune disease or systemic immunosuppressant status are documented.
    • Excluded use: The requested regimen is not combination therapy with intravenous ipilimumab and does not represent another indication excluded by the policy.

    Initial Therapy

    Initial treatment must meet the applicable disease-specific criteria.

    Initial therapy pathways

    • First-line urothelial carcinoma combination therapy: Individual has unresectable, recurrent, or metastatic urothelial carcinoma and is receiving first-line Opdivo Qvantig in combination with cisplatin and gemcitabine.First-line

      NCCN 1, 2A

    • Second-line or subsequent vaginal cancer therapy: Individual has recurrent or metastatic vaginal cancer and is receiving single-agent Opdivo Qvantig as second-line or subsequent therapy for a PD-L1-positive tumor with CPS ≥1%.CPS ≥1%

      NCCN 2A; HPV-related tumor required

    Disease settingThe threshold applies to local or regional recurrence, stage IVB disease, or recurrence with distant metastases.
    Ultra-hypermutated phenotype
    Biomarker statusThe ultra-hypermutated phenotype may be associated with a POLE/POLD1 mutation.
    TMB thresholdThe example threshold is TMB > 50 mut/Mb.
    Related eligibility conditionsApplicable pathways may also require dMMR/MSI-H disease, no prior checkpoint-inhibitor treatment, or no systemic immunosuppressant therapy.
    Ultra-hypermutated phenotype
    TMB thresholdThe ultra-hypermutated phenotype is defined in the cited pathways using TMB > 50 mut/Mb.
    Associated molecular findingA POLE/POLD1 mutation may support the ultra-hypermutated phenotype.
    Applicable cancersThis threshold appears in colorectal and small bowel cancer pathways.
    TMB-high soft tissue sarcoma
    TMB-high thresholdTMB-H is defined as ≥10 mut/Mb for the cited soft tissue sarcoma pathway.
    Disease settingThe pathway applies to advanced or metastatic soft tissue sarcoma and aggressive soft tissue neoplasms.
    Treatment requirementOpdivo Qvantig is used as a single agent.
    NSCLC with brain metastases
    PD-L1 thresholdTumors must have positive PD-L1 expression of ≥1%.
    DiagnosisThe pathway applies to metastatic NSCLC with brain metastases.
    Treatment requirementOpdivo Qvantig is used as a single agent for brain metastases.
    Vaginal cancer
    CPS thresholdThe tumor must be PD-L1 positive with CPS ≥1%.
    DiagnosisThe pathway applies to recurrent or metastatic vaginal cancer.
    Treatment settingOpdivo Qvantig is used as single-agent, second-line or subsequent therapy.
    Performance status
    ECOG requirementWhere specified, the current ECOG performance status must be 0–2.
    Karnofsky alternativeA Karnofsky performance score of 60–100 may satisfy the stated alternative requirement.
    Clinical usePerformance status is used to assess treatment eligibility and disease-related functional status.

    Authorization and Benefit Requirements

    Prior authorization requests must satisfy the applicable clinical criteria, plan requirements, and benefit conditions. Clinical approval does not override member-specific contract limitations or other applicable benefit rules.

    • Review the member’s benefit plan and any applicable preferred-product requirements.
    • Submit the request before treatment when prior authorization is required.
    Step Therapy

    No Venous Access Exception

    Opdivo Qvantig may be approved through the step-therapy pathway only when the individual is unable to use intravenous Opdivo because of no venous access.

    • Document the absence of usable venous access.
    • Do not use this exception solely for convenience or preference.
    Documentation Required

    Clinical Prior-Authorization Documentation

    Provide clinical prior-authorization documentation sufficient to establish the diagnosis, disease extent and stage, treatment setting, regimen, line of therapy, prior treatment history, and supporting clinical findings.

    • Include pathology and diagnostic records, relevant imaging, disease status, and stage.
    • Specify whether treatment is monotherapy or combination therapy and identify all combination agents.
    • Document prior systemic therapy, progression or intolerance where required, performance status, and the proposed line of therapy.
    • Address applicable contraindications, autoimmune disease, immunosuppressive therapy, and prior checkpoint-inhibitor exposure.

    Unsupported block type: documentation

    Documentation Required

    Clinical Indication Documentation

    For each request, document the diagnosis, stage or disease extent, prior treatment, line of therapy, and whether Opdivo Qvantig is being used alone or in the specific combination required by the applicable indication.

    • Identify the applicable labeled or NCCN-supported indication.
    • Include treatment history and the proposed regimen in the authorization request.
    Documentation Required

    Incomplete Molecular Testing

    If tissue is insufficient for complete molecular testing, document attempts to obtain repeat biopsy and/or plasma testing. If those options are not feasible, explain why and provide the available results used to guide treatment.

    • When results remain unknown and testing is not feasible, document the clinical basis for treating the patient as though driver oncogenes are absent, consistent with the policy note.
    Step Therapy

    Step-Therapy Exception Documentation

    The step-therapy exception requires documentation that intravenous Opdivo cannot be used because the individual has no venous access.

    • State the specific venous-access limitation in the request.
    • Requests without this qualifying exception may not satisfy step therapy.
    Denial Risk

    Do Not Combine With Intravenous Ipilimumab

    Do not request or administer Opdivo Qvantig in combination with intravenous ipilimumab (Yervoy). The package insert states that this combination is not indicated and the policy may not approve it.

    • Coverage may be denied for the unapproved Opdivo Qvantig–intravenous ipilimumab combination.
    Denial Risk

    Prior Checkpoint Therapy or Immunosuppression

    Document prior checkpoint-inhibitor exposure and current immunosuppressive therapy. Multiple covered pathways restrict use after another anti-PD-1/PD-L1 or checkpoint inhibitor, after progression on checkpoint therapy, or while receiving systemic immunosuppression for an autoimmune disease or chronic condition.

    • Identify any prior anti-PD-1, anti-PD-L1, or other checkpoint-inhibitor treatment and response or progression.
    • Document whether the individual is receiving systemic immunosuppressive therapy.
    • Failure to meet the applicable prior-therapy or immunosuppression restriction may result in denial.
    Documentation Required

    NSCLC Molecular-Treatment Sequencing

    For NSCLC requests involving EGFR mutations or ALK rearrangements, document progression on the appropriate FDA-approved targeted therapy before requesting Opdivo Qvantig.

    • For resectable NSCLC, document tumor size or nodal status, absence of known EGFR mutations or ALK rearrangements when required, neoadjuvant platinum-doublet use, and planned adjuvant therapy.
    • For metastatic disease with EGFR or ALK aberrations, document progression on FDA-approved targeted treatment.
    Denial Risk

    Nonapproved Use

    Opdivo Qvantig may not be approved for use with intravenous ipilimumab, when the listed criteria are not met, or for other nonapproved indications.

    • Verify that the diagnosis, disease setting, regimen, biomarker, prior therapy, and line-of-therapy requirements are all satisfied.
    • Unapproved combinations or indications are subject to denial.
    Denial Risk

    Failure to Meet Indication Criteria

    Failure to meet any applicable indication criterion may result in denial. The request must support the required prior therapy, biomarker or molecular result, disease stage or extent, performance status, line of therapy, regimen, and relevant exclusion criteria.

    • Address required progression, intolerance, or prior-treatment history.
    • Provide required biomarker findings such as dMMR/MSI-H, PD-L1, CPS, HER2, TMB, or other specified markers.
    • Document required performance status and absence of applicable contraindications or exclusions.
    Denial Risk

    Unapproved Combination or Indication

    Use of Opdivo Qvantig for an unapproved combination or indication, or without meeting the listed coverage criteria, creates a denial risk.

    • The policy does not establish coverage for uses outside the listed FDA-labeled or NCCN-supported pathways.
    • Confirm the proposed regimen and indication before submitting the request.
    Billing Rule

    Preferred-Product Requirement

    Even when Opdivo Qvantig meets the clinical criteria, the benefit plan may require use of a preferred agent or agents.

    • Check the member’s plan for preferred-product requirements before requesting Opdivo Qvantig.
    • Clinical approvability does not eliminate a separate preferred-product condition.
    Step Therapy

    Step Therapy Not Met

    Step therapy is not met unless the request establishes that the individual cannot use intravenous Opdivo because of no venous access.

    • Document the qualifying inability to use intravenous Opdivo in the prior-authorization request.
    • Absent this exception, the request may be denied for failure to meet step therapy.
    Score 1 restricts strenuous activity; score 2 permits self-care but no work activities.
    Score 3–5Score 3 permits only limited self-care, score 4 indicates complete disability, and score 5 means dead.
    Karnofsky Performance Status
    DefinitionA scale used to assess prognosis, functional changes, and ability to tolerate therapy.
    RangeScores range from 0 to 100; lower scores indicate a worse likelihood of survival.
    Relevant thresholdThe cited coverage pathway allows a Karnofsky performance score of 60–100 where specified.
    Neoadjuvant therapy
    DefinitionTreatment given as a first step to shrink a tumor before the main treatment, usually surgery.
    ExamplesExamples include chemotherapy, radiation therapy, and hormone therapy.
    Therapy typeNeoadjuvant therapy is a type of induction therapy.
    Progressive disease
    DefinitionCancer that is growing, spreading, or getting worse.
    AbbreviationProgressive disease is abbreviated PD.
    Coverage contextSeveral pathways require documented disease progression after or during specified prior therapies.
    Refractory disease
    DefinitionIllness or disease that does not respond to treatment.
    Clinical useThe term describes disease that remains unresponsive despite treatment.
    Policy contextThe policy cites relapsed or refractory disease in selected oncology indications.
    Metastasis
    DefinitionThe spread of cancer from one part of the body to another.
    Cell characteristicsMetastatic tumor cells resemble those in the original primary tumor.
    Policy contextThe policy includes metastatic disease and metastatic brain lesions among covered settings when criteria are met.
    Unresectable
    DefinitionUnable to be removed with surgery.
    Clinical usageThe term may describe locally advanced, recurrent, or metastatic disease that cannot be surgically removed.
    Policy contextSeveral covered pathways specify unresectable disease as part of the diagnosis or treatment setting.
    Urothelial carcinoma
    DefinitionA type of bladder cancer occurring in the urinary tract system.
    Covered settingThe policy includes unresectable, recurrent, or metastatic urothelial carcinoma.
    First-line regimenOne pathway specifies first-line treatment in combination with cisplatin and gemcitabine.
    Immune checkpoint inhibitor
    DefinitionA drug that blocks immune-checkpoint proteins and releases immune-system brakes so T cells can better attack cancer cells.
    TargetsExamples include PD-1, PD-L1, and CTLA-4/B7-1/B7-2 checkpoint proteins.
    Policy contextNivolumab in Opdivo Qvantig is a PD-1 immune checkpoint inhibitor.
    dMMR/MSI-H
    dMMRDeficient mismatch repair is abbreviated dMMR.
    MSI-HMicrosatellite instability-high tumor status is abbreviated MSI-H.
    Related phenotypeSome pathways allow a POLE/POLD1 mutation with an ultra-hypermutated phenotype.
    Treatment contextThese biomarker findings are used in selected colorectal, uterine, gastric, small bowel, and other cancer pathways.
    TMB/TMB-H
    TMBTumor mutational burden measures mutations per megabase.
    Ultra-hypermutated thresholdAn ultra-hypermutated phenotype is cited at TMB >50 mut/Mb.
    TMB-H sarcoma thresholdSelected soft tissue sarcoma criteria use TMB-H ≥10 mut/Mb.
    CPS
    DefinitionCPS means combined positive score for PD-L1 expression.
    Vaginal cancer thresholdThe cited recurrent or metastatic vaginal cancer pathway requires CPS ≥1%.
    Treatment contextThe qualifying vaginal cancer regimen is single-agent, second-line or subsequent therapy.
    ECOG performance status
    MeaningECOG performance status is the Eastern Cooperative Oncology Group measure of functional status.
    Common requirementSeveral covered indications require a current score of 0–2.
    Alternative measureFor certain pathways, a Karnofsky score of 60–100 may be used instead.
    Preferred agent
    DefinitionA preferred agent is considered clinically comparable to other agents in the same class or disease category.
    Basis for preferencePreference is based on clinical evidence and cost effectiveness.
    Plan requirementThe benefit plan may require use of a preferred agent even when clinical criteria are met.
    Actionable molecular markers
    MarkersActionable markers include EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, ERBB2 (HER2), and NRG1.
    Testing timingThe NCCN panel recommends testing before initiating therapy to help guide treatment.
    Insufficient tissueIf tissue is insufficient, repeat biopsy and/or plasma testing should be considered.
    Unknown resultsIf testing is not feasible and results remain unknown, patients are treated as though they do not have driver oncogenes.